본문 바로가기
KERD
논문KCI 등재

SARS-CoV-2 Infection and Liver Disease: A Review of Pathogenesis and Outcomes

Baldelli Luke|Marjot Thomas|Barnes Eleanor|Barritt A. Sidney|Webb Gwilym J.|Moon Andrew M.
거트앤리버 소화기연관학회협의회|2023.01|Gut and Liver|제17권 제1호|pp. 12-23|DOI 10.5009/gnl220327

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

COVID-19SARS-CoV-2LiverCirrhosisTropism

초록

The impact of the coronavirus disease 2019 (COVID-19) pandemic has been immense, and it continues to have lasting repercussions. While the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus primarily infects the respiratory system, other organ systems are affected, including the liver. Scientific knowledge on the role of SARS-CoV-2 infection and liver injury has evolved rapidly, with recent data suggesting specific hepatotropism of SARS-CoV-2. Moreover, additional concerns have been raised in regard to long-term liver damage, related to emerging cases of post-COVID-19 cholangiopathy and chronic cholestasis. Great effort has also been focused on studying how specific subpopulations with chronic medical conditions might be disproportionately impacted by COVID-19. One such population includes individuals with chronic liver disease (CLD) and cirrhosis, with an expanding body of research indicating these patients being particularly susceptible to adverse outcomes. In this review, we provide an updated summary on the current pathogenesis and mechanism of liver injury in the setting of SARS-CoV-2 infection, the association between health outcomes and SARS-CoV-2 infection in patients with CLD, and the unique consequences of the COVID-19 pandemic on the routine care of patients with CLD.

Abstract

The impact of the coronavirus disease 2019 (COVID-19) pandemic has been immense, and it continues to have lasting repercussions. While the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus primarily infects the respiratory system, other organ systems are affected, including the liver. Scientific knowledge on the role of SARS-CoV-2 infection and liver injury has evolved rapidly, with recent data suggesting specific hepatotropism of SARS-CoV-2. Moreover, additional concerns have been raised in regard to long-term liver damage, related to emerging cases of post-COVID-19 cholangiopathy and chronic cholestasis. Great effort has also been focused on studying how specific subpopulations with chronic medical conditions might be disproportionately impacted by COVID-19. One such population includes individuals with chronic liver disease (CLD) and cirrhosis, with an expanding body of research indicating these patients being particularly susceptible to adverse outcomes. In this review, we provide an updated summary on the current pathogenesis and mechanism of liver injury in the setting of SARS-CoV-2 infection, the association between health outcomes and SARS-CoV-2 infection in patients with CLD, and the unique consequences of the COVID-19 pandemic on the routine care of patients with CLD.

참고문헌 (104)

  1. Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", Lancet, 395, pp.497~506 (2020)
  2. Marjot T, "Outcomes following SARS-CoV-2 infection in patients with chronic liver disease : an international registry study", J Hepatol, 74, pp.567~577 (2021)
  3. Moon AM, "High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis : preliminary results from an international registry", J Hepatol, 73, pp.705~708 (2020)
  4. Asrani SK, "Burden of liver diseases in the world", J Hepatol, 70, pp.151~171 (2019)
  5. GBD 2017 Cirrhosis Collaborators, "The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017 : a systematic analysis for the global burden of disease study 2017", Lancet Gastroenterol Hepatol, 5, pp.245~266 (2020)
  6. Deutsch-Link S, "Alcohol-associated liver disease mortality increased from 2017 to 2020 and accelerated during the COVID-19 pandemic", Clin Gastroenterol Hepatol, 20, pp.2142~2144 (2022)
  7. Fix OK, "American Association for the Study of Liver Diseases expert panel consensus statement : vaccines to prevent coronavirus disease 2019 infection in patients with liver disease", Hepatology, 74, pp.1049~1064 (2021)
  8. Willuweit K, "Patients with liver cirrhosis show high immunogenicity upon COVID-19 vaccination but develop premature deterioration of antibody titers", Vaccines(Basel), 10, pp.377~ (2022)
  9. Gupta A, "Extrapulmonary manifestations of COVID-19", Nat Med, 26, pp.1017~1032 (2020)
  10. Hundt MA, "Abnormal liver tests in COVID-19 : a retrospective observational cohort study of 1, 827 patients in a major U. S. hospital network", Hepatology, 72, pp.1169~1176 (2020)
  11. Bangash MN, "SARS-CoV-2 : is the liver merely a bystander to severe disease?", J Hepatol, 73, pp.995~996 (2020)
  12. Wang D, "Clinical characteristics of 138hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China", JAMA, 323, pp.1061~1069 (2020)
  13. Mao R, "Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19 : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 5, pp.667~678 (2020)
  14. Zhang Y, "Liver impairment in COVID-19 patients : a retrospective analysis of 115 cases from a single centre in Wuhan city, China", Liver Int, 40, pp.2095~2103 (2020)
  15. Cai Q, "COVID-19 : abnormal liver function tests", J Hepatol, 73, pp.566~574 (2020)
  16. Nardo AD, "Pathophysiological mechanisms of liver injury in COVID-19", Liver Int, 41, pp.20~32 (2021)
  17. Marjot T, "COVID-19 and liver disease : mechanistic and clinical perspectives", Nat Rev Gastroenterol Hepatol, 18, pp.348~364 (2021)
  18. Hartl L, "Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver disease", Hepatology, 76, pp.1563~1575 (2022)
  19. Moon AM, "Elevated liver enzymes in patients with COVID-19 : look, but not too hard", Dig Dis Sci, 66, pp.1767~1769 (2021)
  20. Balderramo D, "Abnormal liver tests during hospitalization predict mortality in patients with COVID-19 : a multicenter study from South America", Can J Gastroenterol Hepatol, 2021, pp.1622533~ (2021)
  21. Yip TC, "Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19", Gut, 70, pp.733~742 (2021)
  22. Lei F, "Longitudinal association between markers of liver injury and mortality in COVID-19 in China", Hepatology, 72, pp.389~398 (2020)
  23. Bloom PP, "Liver biochemistries in hospitalized patients with COVID-19", Hepatology, 73, pp.890~900 (2021)
  24. Fu Y, "Clinical features of patients infected with coronavirus disease 2019 with elevated liver biochemistries : a multicenter, retrospective study", Hepatology, 73, pp.1509~1520 (2021)
  25. Song Jeong Eun, "Multicenter Analysis of Clinical Features and Prognosis of COVID-19 Patients with Hepatic Impairment", Gut and Liver, 15(4), pp.606~615 (2021), 거트앤리버 소화기연관학회협의회[DOI]
  26. Weber S, "Liver function test abnormalities at hospital admission are associated with severe course of SARS-CoV-2infection : a prospective cohort study", Gut, 70, pp.1925~1932 (2021)
  27. Wang T, "Longitudinal analysis of the utility of liver biochemistry as prognostic markers in hospitalized patients with corona virus disease 2019", Hepatol Commun, 5, pp.1586~1604 (2021)
  28. Zhou F, "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China : a retrospective cohort study", Lancet, 395, pp.1054~1062 (2020)
  29. Faruqui S, "Cholangiopathy after severe COVID-19 : clinical features and prognostic implications", Am J Gastroenterol, 116, pp.1414~1425 (2021)
  30. Roth NC, "Post-COVID-19 cholangiopathy : a novel entity", Am J Gastroenterol, 116, pp.1077~1082 (2021)
  31. Edwards K, "Secondary sclerosing cholangitis in critically ill patients : a rare disease precipitated by severe SARS-CoV-2 infection", BMJ Case Rep, 13, pp.e237984~ (2020)
  32. Laurent L, "Cholangiopathy in critically ill patients surviving beyond the intensive care period : a multicentre survey in liver units", Aliment Pharmacol Ther, 46, pp.1070~1076 (2017)
  33. Bütikofer S, "Secondary sclerosing cholangitis as cause of persistent jaundice in patients with severe COVID-19", Liver Int, 41, pp.2404~2417 (2021)
  34. Wiersinga WJ, "Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019(COVID-19) : a review", JAMA, 324, pp.782~793 (2020)
  35. Da BL, "Liver injury in patients hospitalized with coronavirus disease 2019 correlates with hyperinflammatory response and elevated interleukin-6", Hepatol Commun, 5, pp.177~188 (2020)
  36. Olry A, "Drug-induced liver injury and COVID-19 infection : the rules remain the same", Drug Saf, 43, pp.615~617 (2020)
  37. Jothimani D, "COVID-19 and the liver", J Hepatol, 73, pp.1231~1240 (2020)
  38. Lagana SM, "Hepatic pathology in patients dying of COVID-19 : a series of 40 cases including clinical, histologic, and virologic data", Mod Pathol, 33, pp.2147~2155 (2020)
  39. Díaz LA, "High prevalence of hepatic steatosis and vascular thrombosis in COVID-19 : a systematic review and meta-analysis of autopsy data", World J Gastroenterol, 26, pp.7693~7706 (2020)
  40. Mohammed SA, "Liver injury with COVID-19 : laboratory and histopathological outcome-systematic review and meta-analysis", Egypt Liver J, 12, pp.9~ (2022)
  41. Sonzogni A, "Liver histopathology in severe COVID 19 respiratory failure is suggestive of vascular alterations", Liver Int, 40, pp.2110~2116 (2020)
  42. Xu Z, "Pathological findings of COVID-19 associated with acute respiratory distress syndrome", Lancet Respir Med, 8, pp.420~422 (2020)
  43. Pirola CJ, "SARS-CoV-2 virus and liver expression of host receptors : putative mechanisms of liver involvement in COVID-19", Liver Int, 40, pp.2038~2040 (2020)
  44. Qi F, "Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses", Biochem Biophys Res Commun, 526, pp.135~140 (2020)
  45. Wang Y, "SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19", J Hepatol, 73, pp.807~816 (2020)
  46. Wanner N, "Molecular consequences of SARS-CoV-2 liver tropism", Nat Metab, 4, pp.310~319 (2022)
  47. Barnes E, "Infection of liver hepatocytes with SARS-CoV-2", Nat Metab, 4, pp.301~302 (2022)
  48. Ji D, "Non-alcoholic fatty liver diseases in patients with COVID-19 : a retrospective study", J Hepatol, 73, pp.451~453 (2020)
  49. Zhou YJ, "Younger patients with MAFLD are at increased risk of severe COVID-19 illness : a multicenter preliminary analysis", J Hepatol, 73, pp.719~721 (2020)
  50. Williamson EJ, "Factors associated with COVID-19-related death using opensafely", Nature, 584, pp.430~436 (2020)
  51. Lopez-Mendez I, "Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection(COVID-19)", Ann Hepatol, 20, pp.100271~ (2021)
  52. Ioannou GN, "Cirrhosis and severe acute respiratory syndrome coronavirus 2 infection in US veterans : risk of infection, hospitalization, ventilation, and mortality", Hepatology, 74, pp.322~335 (2021)
  53. Marjot T, "SARS-CoV-2 infection in patients with autoimmune hepatitis", J Hepatol, 74, pp.1335~1343 (2021)
  54. Butt AA, "Mortality is not increased in SARS-CoV-2 infected persons with hepatitis C virus infection", Liver Int, 41, pp.1824~1831 (2021)
  55. Roca-Fernández A, "Hepatic steatosis, rather than underlying obesity, increases the risk of infection and hospitalization for COVID-19", Front Med(Lausanne), 8, pp.636637~ (2021)
  56. Yoo HW, "COVID-19 morbidity and severity in patients with nonalcoholic fatty liver disease in South Korea : a nationwide cohort study", Clin Gastroenterol Hepatol, 20, pp.e1217~e1218 (2022)
  57. Yip TC, "Current and past infections of HBV do not increase mortality in patients with COVID-19", Hepatology, 74, pp.1750~1765 (2021)
  58. Ge J, "Outcomes of SARS-CoV-2 infection in patients with chronic liver disease and cirrhosis : a national COVID cohort collaborative study", Gastroenterology, 161, pp.1487~1501 (2021)
  59. Kim D, "Predictors of outcomes of COVID-19 in patients with chronic liver disease : US multicenter study", Clin Gastroenterol Hepatol, 19, pp.1469~1479 (2021)
  60. Dongsub Jeon, "Impact of liver cirrhosis on the clinical outcomes of patients with COVID-19: a nationwide cohort study of Korea", The Korean Journal of Internal Medicine, 36(5), pp.1092~1101 (2021), 대한내과학회[DOI]
  61. Pose E, "Programmed death ligand 1 is overexpressed in liver macrophages in chronic liver diseases, and its blockade improves the antibacterial activity against infections", Hepatology, 74, pp.296~311 (2021)
  62. Piano S, "Infections complicating cirrhosis", Liver Int, 38(Suppl 1), pp.126~133 (2018)
  63. Schütte A, "Influenza virus infection as precipitating event of acute-on-chronic liver failure", J Hepatol, 70, pp.797~799 (2019)
  64. Richardson S, "Presenting characteristics, comorbidities, and outcomes among 5700patients hospitalized with COVID-19 in the New York City area", JAMA, 323, pp.2052~2059 (2020)
  65. Kompaniyets L, "Underlying medical conditions and severe illness among 540, 667adults hospitalized with COVID-19, March 2020-March 2021", Prev Chronic Dis, 18, pp.E66~ (2021)
  66. Li J, "Mendelian randomization analysis reveals no causal relationship between nonalcoholic fatty liver disease and severe COVID-19", Clin Gastroenterol Hepatol, 20, pp.1553~1560 (2022)
  67. Liu D, "Assessing causal relationships between COVID-19 and non-alcoholic fatty liver disease", J Hepatol, 76, pp.740~742 (2022)
  68. Szabo G, "Alcohol's effect on host defense", Alcohol Res, 37, pp.159~170 (2015)
  69. Takeuchi O, "Innate immunity to virus infection", Immunol Rev, 227, pp.75~86 (2009)
  70. Simou E, "The effect of alcohol consumption on the risk of ARDS : a systematic review and meta-analysis", Chest, 154, pp.58~68 (2018)
  71. Moss M, "The role of chronic alcohol abuse in the development of acute respiratory distress syndrome in adults", JAMA, 275, pp.50~54 (1996)
  72. Moss M, "Chronic alcohol abuse is associated with an increased incidence of acute respiratory distress syndrome and severity of multiple organ dysfunction in patients with septic shock", Crit Care Med, 31, pp.869~877 (2003)
  73. Boé DM, "Alcohol abuse and pulmonary disease", J Leukoc Biol, 86, pp.1097~1104 (2009)
  74. Fan AZ, "Patterns of alcohol consumption and the metabolic syndrome", J Clin Endocrinol Metab, 93, pp.3833~3838 (2008)
  75. Shankar A, "The association among smoking, heavy drinking, and chronic kidney disease", Am J Epidemiol, 164, pp.263~271 (2006)
  76. "FXR inhibition reduces ACE2 expression, SARS-CoV-2 infection and may improve COVID-19 outcome" (2021)[URL]
  77. "Stay up to date with your COVID-19 vaccines including boosters" (2022)[URL]
  78. "Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare professionals" (2022)[URL]
  79. Cornberg M, "EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients", J Hepatol, 74, pp.944~951 (2021)
  80. Ju-Yeon Cho, "Update on liver disease management during the pandemic of coronavirus disease 2019 (COVID-19): 2021 KASL guideline", Clinical and Molecular Hepatology, 27(4), pp.515~523 (2021), 대한간학회[DOI]
  81. Ju-Yeon Cho, "Management of liver diseases during the pandemic of coronavirus disease-19", Clinical and Molecular Hepatology, 26(3), pp.243~250 (2020), 대한간학회[DOI]
  82. Wang J, "Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease(CHESS2101) : a multicenter study", J Hepatol, 75, pp.439~441 (2021)
  83. Wang J, "Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis : a prospective multicenter study", Hepatol Int, 16, pp.691~701 (2022)
  84. Marjot T, "Humoral and cellular immune responses to SARS-CoV-2 vaccination across multiple vaccine platforms and liver disease types : an EASL registry multicentre prospective cohort study", J Hepatol, 77, pp.S54~S55 (2022)
  85. Boettler T, "SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis", J Hepatol, 77, pp.653~659 (2022)
  86. Rüther DF, "Autoimmune hepatitis and COVID-19 : no increased risk for AIH after vaccination but reduced care", J Hepatol, 77, pp.250~251 (2022)
  87. Chong CR, "Safety of inactivated influenza vaccine in cancer patients receiving immune checkpoint inhibitors", Clin Infect Dis, 70, pp.193~199 (2020)
  88. Walle T, "Cytokine release syndromelike serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy", Nat Cancer, 3, pp.1039~1051 (2022)
  89. Moon AM, "SARS-CoV-2infections among patients with liver disease and liver transplantation who received COVID-19 vaccination", Hepatol Commun, 6, pp.889~897 (2022)
  90. John BV, "Association of BNT162b2 mRNA and mRNA-1273 vaccines with COVID-19 infection and hospitalization among patients with cirrhosis", JAMA Intern Med, 181, pp.1306~1314 (2021)
  91. John BV, "Effectiveness of COVID-19 Viral Vector Ad. 26. COV2. S vaccine and comparison with mRNA vaccines in cirrhosis", Clin Gastroenterol Hepatol, 20, pp.2405~2408 (2022)
  92. Marjot T, "SARS-CoV-2 vaccination in patients with liver disease : responding to the next big question", Lancet Gastroenterol Hepatol, 6, pp.156~158 (2021)
  93. Issaka RB, "Real-world data on the impact of COVID-19 on endoscopic procedural delays", Clin Transl Gastroenterol, 12, pp.e00365~ (2021)
  94. Calderwood AH, "Impact of the COVID-19 pandemic on utilization of EGD and colonoscopy in the United States : an analysis of the GIQuIC registry", Tech Innov Gastrointest Endosc, 23, pp.313~321 (2021)
  95. Mahmud N, "Changes in hepatocellular carcinoma surveillance and risk factors for noncompletion in the Veterans Health Administration cohort during the coronavirus disease 2019pandemic", Gastroenterology, 160, pp.2162~2164 (2021)
  96. Kim NJ, "The COVID-19 pandemic highlights opportunities to improve hepatocellular carcinoma screening and diagnosis in a national health system", Am J Gastroenterol, 117, pp.678~684 (2022)
  97. Muñoz-Martínez S, "Assessing the impact of COVID-19 on liver cancer management(CERO-19)", JHEP Rep, 3, pp.100260~ (2021)
  98. Gandhi M, "Impact of COVID-19on hepatocellular carcinoma management : a multicountry and region study", J Hepatocell Carcinoma, 8, pp.1159~1167 (2021)
  99. Blach S, "Impact of COVID-19on global HCV elimination efforts", J Hepatol, 74, pp.31~36 (2021)
  100. Moon AM, "Alcohol-associated liver disease before and after COVID-19 : an overview and call for ongoing investigation", Hepatol Commun, 5, pp.1616~1621 (2021)
  101. Kang E, "Impact of the COVID-19 pandemic on the health status and behaviors of adults in Korea : national cross-sectional web-based selfreport survey", JMIR Public Health Surveill, 7, pp.e31635~ (2021)
  102. Serper M, "Positive early patient and clinician experience with telemedicine in an academic gastroenterology practice during the COVID-19 pandemic", Gastroenterology, 159, pp.1589~1591 (2020)
  103. Kim HS, "COVID-19 case surge and telemedicine utilization in a tertiary hospital in Korea", Telemed J E Health, 28, pp.666~674 (2022)
  104. Wegermann K, "Racial and socioeconomic disparities in utilization of telehealth in patients with liver disease during COVID-19", Dig Dis Sci, 67, pp.93~99 (2022)

관련 논문AI추천

Coronavirus Disease 2019-Liver Injury- Literature Review and Guidelines Based on the Recommendations of Hepatological SocietiesDariusz M. Lebensztejn, Irena Jankowska, Joanna Pawlowska대한소아소화기영양학회 · Pediatric Gastroenterology, Hepatology & Nutrition2021 · 제24권 제2호Clinical outcomes of coronavirus disease 2019 in patients with pre-existing liver diseases: A multicenter study in South KoreaByoung Kuk Jang, Byung Seok Kim, Chang Hyeong Lee, Hyun Jung Kim, Jae Seok Hwang, Jeong Eun Song, Jeong Ill Suh, Jung Gil Park, Min Kyu Kang, Se Young Jang, Soo Young Park, Won Young Tak, Woo Jin Chung, Young Oh Kweon, Yu Rim Lee대한간학회 · Clinical and Molecular Hepatology2020 · 제26권 제4호Impact of liver cirrhosis on the clinical outcomes of patients with COVID-19: a nationwide cohort study of KoreaDongsub Jeon, Jonggi Choi, Minkook Son대한내과학회 · The Korean Journal of Internal Medicine2021 · 제36권 제5호Changing Features of Liver Injury in COVID-19 Patients: Impact of Infection with the SARS-CoV-2 Delta (B.1.617.2) VariantsChin Bum Sik, Choi Chang Wan, Choi Jongkyoung, Jeong Jae Yoon, Kim Yeonjae, Kwon Hyeok Choon, Lim Dae Hyun, Nam Seongwoo, Sung Ho Kyung대한감염학회 · Infection and Chemotherapy2022 · 제54권 제4호Multicenter Analysis of Clinical Features and Prognosis of COVID-19 Patients with Hepatic Impairment김병석, 정우진, Daegu-Gyeongbuk Liver Study Group, Hwang Jae Seok, Jang Byoung Kuk, Jang Se Young, Jang Won Young, Kang Min Kyu, Kweon Young Oh, Lee Chang Hyeong, Lee Yu Rim, Park Jung Gil, Park Soo Young, Song Jeong Eun, Suh Jeong Ill, Tak Won Young거트앤리버 소화기연관학회협의회 · Gut and Liver2021 · 제15권 제4호Management of liver diseases during the pandemic of coronavirus disease-19송도선, Jeong Hoon Lee, Ji Hoon Kim, Ju-Yeon Cho, Korean Association for the Study of the Liver, Soon Sun Kim, Young-Sun Lee대한간학회 · Clinical and Molecular Hepatology2020 · 제26권 제3호

이 간행물의 다른 논문 (20건)

Changes in Metabolic Parameters by Helicobacter pylori Eradication According to Sex Differences김성은pp. 1-2Clinical Relevance of Helicobacter pylori Coinfection in Ebstein-Barr Virus-Associated Gastric CarcinomaLee Bong Eunpp. 3-5High Fatty Liver Index and Fracture Risk: Clinical ImplicationsHong Namkipp. 6-7Sarcopenic Obesity, the Possible Culprit for Nonalcoholic Fatty Liver Disease or FibrosisYoon Eileen L., Kang Seong Heepp. 8-9Are the Immunohistochemistry-Based Biomarkers Helpful for Predicting Prognosis in Patients with Surgically Resected Cholangiocarcinoma?김동욱pp. 10-11
원문 보기